Zhejiang Garden Biopharmaceutical(300401.SZ): Obtained the drug registration certificate for Apovastatin Calcium Tablets (I)

Zhejiang Garden Biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary Zhejiang Garden Pharmaceutical Co., Ltd. (hereinafter referred to as "Garden Pharmaceutical") recently received the "Drug Registration Certificate" for "Ezetimibe Atorvastatin Calcium Tablets (I)" issued by the National Medical Products Administration. Ezetimibe Atorvastatin Calcium Tablets (I) are mainly used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). According to data from Minet, the market size of Ezetimibe Atorvastatin Calcium Tablets (I) in public medical institutions is expected to reach approximately 56.6 million RMB by 2025.